U S Dialysis was Davita’s largest segment in fiscal 2025, bringing in $6.74B of $7.73B (87%).
| Segment | FY 2008 | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U S Dialysis | — | $6.10B | $6.37B | $6.74B | |||||||||||||
| U.S. Dialysis | $6.04B | — | — | — | |||||||||||||
| U.S. Dialysis & Related Lab Services | — | — | — | — | |||||||||||||
| Guarantor Subsidiaries | — | — | — | — | |||||||||||||
| Non-Guarantor Subsidiaries | — | — | — | — | |||||||||||||
| Other - Ancillary Services | $223.22M | $500.14M | $717.74M | $914.39M | |||||||||||||
| Other Ancillary Services & Strategic Initiatives | — | — | — | — | |||||||||||||
| Other-Ancillary Services & Strategic Initiatives | — | — | — | — | |||||||||||||
| Davita Healthcare Partners Inc | — | — | — | — | |||||||||||||
| Davita Inc | — | — | — | — | |||||||||||||
| Other Operating Segments With Intersegment | $692.34M | $751.42M | $13.91M | $11.20M | |||||||||||||
| Healthcare Partners (Hcp) | — | — | — | — | |||||||||||||
| Davita Medical Group (Dmg) | — | — | — | — | |||||||||||||
| U S Dialysis & Related Lab Services With Intersegment | $87.05M | $88.22M | $71.75M | $60.96M | |||||||||||||
| Intersegment Elimination | — | — | — | — | |||||||||||||
| Consolidating Adjustments | — | — | — | — | |||||||||||||
| Total | $7.04B | $7.44B | $7.18B | $7.73B |
Davita brought in $7.73B from its four segments in fiscal 2025, the year ended December 31, 2025. That is less than the $12.33B it reports by health care organization revenue sources, so these segments do not cover all of its revenue. U S Dialysis was the largest at $6.74B (87.2%), ahead of Other - Ancillary Services at $914.39M (11.8%) and U S Dialysis & Related Lab Services With Intersegment at $60.96M (0.8%). The remaining segment, Other Operating Segments With Intersegment, brought in $11.20M.
Compared with fiscal 2024, Other - Ancillary Services grew 27.4% to $914.39M and U S Dialysis grew 5.7% to $6.74B.
Davita began breaking out U S Dialysis in fiscal 2023, when it brought in $6.10B. Davita stopped reporting U.S. Dialysis as a separate segment after fiscal 2022, when it brought in $6.04B.
Medicare & Medicare Advantage was Davita’s largest revenue line in fiscal 2025, bringing in $6.74B of $12.33B (55%).
| Health Care Organization Revenue Sources | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Medicare & Medicare Advantage | $6.04B | $6.10B | $6.37B | $6.74B | ||||
| Commercial Payors | $3.44B | $3.62B | $3.78B | $3.81B | ||||
| Other Government Payors | $1.14B | $1.35B | $717.74M | $914.39M | ||||
| Medicaid & Managed Medicaid | $759.58M | $833.74M | $863.95M | $871.70M | ||||
| Total | $11.38B | $11.91B | $11.74B | $12.33B |
Davita brought in $12.33B from its four revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 5.0% from $11.74B in fiscal 2024. Medicare & Medicare Advantage was the largest at $6.74B (54.7%), ahead of Commercial Payors at $3.81B (30.9%) and Other Government Payors at $914.39M (7.4%). The remaining revenue line, Medicaid & Managed Medicaid, brought in $871.70M.
Compared with fiscal 2024, Other Government Payors grew fastest, up 27.4% to $914.39M. Every revenue line above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these revenue lines grew from $11.38B to $12.33B, a compound annual growth rate of 2.7%. Medicare & Medicare Advantage's share of the total rose from 53.1% to 54.7%.
Davita (DVA) reports its revenue by segment and by health care organization revenue sources. In fiscal 2025, U S Dialysis was its largest segment, bringing in $6.74B (87.2% of the total), followed by Other - Ancillary Services at $914.39M (11.8%).
U S Dialysis was Davita's largest segment in fiscal 2025, bringing in $6.74B, or 87.2% of the $7.73B total across its four segments.
Medicare & Medicare Advantage was Davita's largest revenue line in fiscal 2025, bringing in $6.74B, or 54.7% of the $12.33B total across its four revenue lines.
Other - Ancillary Services grew faster than U S Dialysis in fiscal 2025, up 27.4% from $717.74M to $914.39M. U S Dialysis grew 5.7% to $6.74B.
Every figure comes from Davita's annual financial filings, as reported. Each line keeps the name Davita gives it, and years follow its fiscal calendar.
Davita's revenue by segment goes back to fiscal 2008, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.